Cover Image
Market Research Report

United States Anesthesia Drugs Market, By Type (Local, General Inhalation, General Intravenous) & Companies

Published by Renub Research Product code 320845
Published Content info 136 Pages
Delivery time: 1-2 business days
Price
Back to Top
United States Anesthesia Drugs Market, By Type (Local, General Inhalation, General Intravenous) & Companies
Published: June 8, 2018 Content info: 136 Pages
Description

Anesthesia is a medicine which is given to relieve pain and sensation during surgery. Drugs render a patient unresponsive and unconscious. United States Anesthesia Drugs Market is projected to reach US$ 5 Billion by the year 2024 owing to the increasing prevalence of cardiovascular cases, rising geriatric population and growing number of urgent surgeries in the United States. The different types of anesthesia are Local Anesthesia, General Inhalation Anesthesia and General Intravenous Anesthesia. Local Anesthesia and General Anesthesia are the two commonly used types of anesthesia. Local anesthesia is a condition when sensation within a specific body part in inhibited, where as general anesthesia results in loss of consciousness and sensation. Furthermore, the public and private health insurers' consideration of adding anesthetic products in their reimbursement policy is expected to boost the US anesthesia drugs market in the recent years.

All Major Companies Losing their Market Share

In United States all established companies are losing their market share. Primarily because anesthesia drugs are mostly sold in generic form as it is available in the low cost. The companies studied in the report are Baxter International Inc, Endo International plc & AbbVie. Today, with the help of anesthesia medical facilities, performs various surgeries to treat patient's deformities in the field of trauma, cardiovascular, gastrointestinal, urological, orthopedics, ophthalmology, neurology, oncology and cosmetics.

Renub Research report titled “United States Anesthesia Drugs Market, By Type [General Inhalation Anesthesia, General Intravenous Anesthesia (Propofol, Benzodiazepines Class, Fospropofol Disodium, Ketamine, Methohexital Sodium, Pentobarbital, Etomidate & Fentanyl) and Local Anesthesia (Articaine, Bupivacaine, Lidocaine, Mepivacaine & Prilocaine], Companies (Baxter International, Endo International plc, AbbVie & Others)” provides a complete analysis of United States Anesthesia Drugs Market.

By Type - General Intravenous Anesthesia leads the Market but Local Anesthesia Drugs is the Future

The report studies the market of the following Anesthesia Drugs segments: General Inhalation Anesthesia, General Intravenous Anesthesia can be further subdivided into (Propofol, Benzodiazepines Class, Fospropofol Disodium, Ketamine, Methohexital Sodium, Pentobarbital, Etomidate & Fentanyl), Among these anesthesia, Propofol and Benzodiazepines Class are the leading anesthesia drugs. Local Anesthesia is further segmented into (Articaine, Bupivacaine, Lidocaine, Mepivacaine & Prilocaine). Among these Articaine and Lidocaine have good market share.

Companies Analysis

Baxter International, Endo International plc, and AbbVie are some of the top companies operating in the United States Anesthesia Drugs Market; which has been studied thoroughly in the report.

This market research report provides a complete analysis of the United States Anesthesia Drugs Market and their projections for the upcoming years, Growth Drivers, Challenges, and Reimbursement policy.

Client can purchase this report in sections through Purchase by Chapter Tab given above

By Type - United States Anesthesia Drugs Market

1. General Inhalation Anesthesia

2. General Intravenous Anesthesia

  • Propofol
  • Benzodiazepines Class
  • Fospropofol Disodium
  • Ketamine
  • Methohexital Sodium
  • Pentobarbital
  • Etomidate
  • Fentanyl

3. Local Anesthesia

  • Articaine
  • Bupivacaine
  • Lidocaine
  • Mepivacaine
  • Prilocaine

Key Players Sales - United States Anesthetic Drugs Market

  • 1. Baxter International Inc
  • 2. Endo International plc
  • 3. AbbVie

This Report provides the answer of following Questions:

  • What will be the United States Anesthesia Drugs Market by 2024?
  • What will be the United States Local Anesthesia Drugs Market for the year 2024?
  • What was the United States General Inhalation Anesthesia Drugs Market in 2017?
  • Among General Inhalation, General Intravenous and Local Anesthesia; which one is driving the United States Anesthesia Drugs Market?
  • What are the key driving forces for United States Anesthesia Drugs Market?
  • What are the key challenges to United States Anesthesia Drugs Market?
Table of Contents

Table of Contents

1. Executive Summary

2. United States Anesthesia Drugs Market

3. Market Share-United States Anesthesia Drugs

  • 3.1. Anesthesia Drugs
  • 3.2. General Intravenous Anesthesia Drugs
  • 3.3. Local Anesthesia Drugs
  • 3.4. Company

4. Market-United States Anesthesia Drugs Types

  • 4.1. General Inhalation Anesthesia Drugs Market
  • 4.2. General Intravenous Anesthesia Drugs Market
  • 4.3. Local Anesthesia Drugs Market

5. Market-General Intravenous Anesthesia Drugs

  • 5.1. Propofol
  • 5.2. Benzodiazepines Class (Diazepam and Midazolam)
  • 5.3. Fospropofol Disodium
  • 5.4. Ketamine
  • 5.5. Methohexital Sodium
  • 5.6. Pentobarbital
  • 5.7. Etomidate
  • 5.8. Fentanyl

6. Market-Local Anesthesia Drugs

  • 6.1. Articaine
  • 6.2. Bupivacaine
  • 6.3. Lidocaine
  • 6.4. Mepivacaine
  • 6.5. Prilocaine

7. Companies-United States Anesthesia Drugs Market

  • 7.1. Baxter International Inc. Anesthesia Drugs Sales
  • 7.2. Endo International plc Anesthesia Drugs Sales
  • 7.3. AbbVie Anesthesia Drugs Sales
  • 7.4. Other Companies Anesthetic Drugs Sales

8. Merger & Acquisition (M&A)-United States Anesthesia

9. Reimbursement Policy-Private Health Insurance Providers

  • 9.1. Aetna International
  • 9.2. Coventry Health Care
  • 9.3. Anthem Blue Cross and Blue Shield
  • 9.4. Blue Cross and Blue Shield of Texas
  • 9.5. United Healthcare
    • 9.5.1. State Exceptions

10. Reimbursement Policy-Public Health Insurance Providers

  • 10.1. Medicare
  • 10.2. MDWise

11. Growth Drivers

  • 11.1. Growing Demand for Anesthesia Service
  • 11.2. Rise in Ageing Population & Prevalence of Cardiovascular Disease in United States

12. Challenges

  • 12.1. Un-match Anesthesia Providers in United States
  • 12.2. Shortage of Anesthesia Drugs in United States

List of Figures:

  • Figure 2-1: United States-Anesthesia Drugs Market (Million US$), 2011-2017
  • Figure 2-2: United States-Forecast for Anesthesia Drugs Market (Million US$), 2018-2024
  • Figure 3-1: United States-Anesthesia Drugs Market Share by Type (Percent), 2011-2017
  • Figure 3-2: United States-Forecast for Anesthesia Drugs Market Share by Type (Percent), 2018-2024
  • Figure 3-3: United States-General Intravenous Anesthesia Drugs Market Share (Percent), 2011-2017
  • Figure 3-4: United States-Forecast for General Intravenous Anesthesia Drugs Market Share (Percent), 2018-2024
  • Figure 3-5: United States-Local Anesthesia Drugs Market Share (Percent), 2011-2017
  • Figure 3-6: United States-Forecast for Local Anesthesia Drugs Market Share (Percent), 2018-2024
  • Figure 3-7: United States-Anesthesia Drugs Market Share by Company (Percent), 2011-2017
  • Figure 3-8: United States-Forecast for Anesthesia Drugs Market Share by Company (Percent), 2018-2024
  • Figure 4-1: United States-General Inhalation Anesthesia Drugs Market (Million US$), 2011-2017
  • Figure 4-2: United States-Forecast for General Inhalation Anesthesia Drugs Market (Million US$), 2018-2024
  • Figure 4-3: United States-General Intravenous Anesthesia Drugs Market (Million US$), 2011-2017
  • Figure 4-4: United States-Forecast for General Intravenous Anesthesia Drugs Market (Million US$), 2018-2024
  • Figure 4-5: United States-Local Anesthesia Drugs Market (Million US$), 2011-2017
  • Figure 4-6: United States-Forecast for Local Anesthesia Drugs Market (Million US$), 2018-2024
  • Figure 5-1: United States-Propofol Market (Million US$), 2011-2017
  • Figure 5-2: United States-Forecast for Propofol Market (Million US$), 2018-2024
  • Figure 5-3: United States-Benzodiazepines Class Market (Million US$), 2011-2017
  • Figure 5-4: United States-Forecast for Benzodiazepines Class Market (Million US$), 2018-2024
  • Figure 5-5: United States-Fospropofol Disodium Market (Million US$), 2011-2017
  • Figure 5-6: United States-Forecast for Fospropofol Disodium Market (Million US$), 2018-2024
  • Figure 5-7: United States-Ketamine Market (Million US$), 2011-2017
  • Figure 5-8: United States-Forecast for Ketamine Market (Million US$), 2018-2024
  • Figure 5-9: United States-Methohexital Sodium Market (Million US$), 2011-2017
  • Figure 5-10: United States-Forecast for Methohexital Sodium Market (Million US$), 2018-2024
  • Figure 5-11: United States-Pentobarbital Market (Million US$), 2011-2017
  • Figure 5-12: United States-Forecast for Pentobarbital Market (Million US$), 2018-2024
  • Figure 5-13: United States-Etomidate Market (Million US$), 2011-2017
  • Figure 5-14: United States-Forecast for Etomidate Market (Million US$), 2018-2024
  • Figure 5-15: United States-Fentanyl Market (Million US$), 2011-2017
  • Figure 5-16: United States-Forecast for Fentanyl Market (Million US$), 2018-2024
  • Figure 6-1: United States-Articaine Market (Million US$), 2011-2017
  • Figure 6-2: United States-Forecast for Articaine Market (Million US$), 2018-2024
  • Figure 6-3: United States-Bupivacaine Market (Million US$), 2011-2017
  • Figure 6-4: United States-Forecast for Bupivacaine Market (Million US$), 2018-2024
  • Figure 6-5: United States-Lidocaine Market (Million US$), 2011-2017
  • Figure 6-6: United States-Forecast for Lidocaine Market (Million US$), 2018-2024
  • Figure 6-7: United States-Mepivacaine Market (Million US$), 2011-2017
  • Figure 6-8: United States-Forecast for Mepivacaine Market (Million US$), 2018-2024
  • Figure 6-9: United States-Prilocaine Market (Million US$), 2011-2017
  • Figure 6-10: United States-Forecast for Prilocaine Market (Million US$), 2018-2024
  • Figure 7-1: United States-Baxter International Anesthesia Drugs Sales (Million US$), 2011-2017
  • Figure 7-2: United States-Forecast for Baxter International Anesthesia Drugs Sales (Million US$), 2018-2024
  • Figure 7-3: United States-Endo International plc Anesthesia Drugs Sales (Million US$), 2011-2017
  • Figure 7-4: United States-Forecast for Endo International plc Anesthesia Drugs Sales (Million US$), 2018-2024
  • Figure 7-5: United States-AbbVie Anesthesia Drugs Sales (Million US$), 2011-2017
  • Figure 7-6: United States-Forecast for AbbVie Anesthesia Drugs Sales (Million US$), 2018-2024
  • Figure 7-7: United States-Other Companies Anesthesia Drugs Sales (Million US$), 2011-2017
  • Figure 7-8: United States-Forecast for Other Companies Anesthesia Drugs Sales (Million US$), 2018-2024
  • Figure 11-1: United States-Cosmetic Procedures (Number), 1997, 2012-2013, 2015-2016
  • Figure 11-2: United States-Ageing Population by Age Group (Thousand), 2012-2016
  • Figure 12-1: United States-By Region Availability of Anesthesia Specialists (Percent), 2010
  • Figure 12-2: United States-By States Availability of Anesthesia Specialists (Percent), 2010
  • Figure 12-3: United States-Drugs Shortage (Number), 2001-2015
  • Figure 12-4: United States-Anesthesia Drugs Shortage with the Highest Frequency (Percent), 2012

List of Table:

  • Table 8-1: United States-Anesthesia Market Merger & Acquisitions (M&A), Jan 2016-March 2017
  • Table 9-1: Coventry Health Care-Anesthesia Modifiers, 2016
  • Table 9-2: Blue Cross and Blue Shield of Texas-Physical Status Modifiers, 2017
  • Table 9-3: Blue Cross and Blue Shield of Texas-Qualifying Circumstances, 2017
  • Table 9-4: Blue Cross and Blue Shield of Texas-Modifier Information Billed by an Anesthesiologist, 2017
  • Table 9-5: Blue Cross and Blue Shield of Texas-Modifier Information Billed by a CRNA, 2017
  • Table 9-6: Blue Cross and Blue Shield of Texas-Anesthesia Modifier Reimbursement
  • Table 9-7: UnitedHealthcare Community-Modifiers, 2017
  • Table 10-1: Medicare-Reimbursement Formulas
  • Table 10-2: Medicare-General and Monitored Anesthesia Care
  • Table 10-3: Medicare-Anesthesia Modifiers, 2017
  • Table 10-4: MDwise-Type of Service & PA Requirement
  • Table 10-5: MDwise-Anesthesia Time Table, 2017
  • Table 10-6: MDwise-Qualifying Circumstances, 2017
  • Table 10-7: MDwise-Status Modifiers, 2017
  • Table 11-1: United States-Cardiovascular Disease Prevalence (Percent), 2010,2015,2020,2025, 2030
Back to Top